Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J crossed by Red Cross?

This article was originally published in The Gray Sheet

Executive Summary

Johnson & Johnson is suing the American Red Cross for violating its exclusive trademark rights to the Red Cross design and use of the word "Red Cross" on commercial products. The suit, filed Aug. 8 in New York federal court, cites ARC's licensing of the trademark - used by J&J on first-aid supplies since 1887 - to businesses selling products including baby mitts, combs and humidifiers, and notes the organization only has rights to the emblem in connection with non-profit relief services. ARC called the suit "obscene," explaining that it has taken the step to license the emblem to expand access to emergency preparedness supplies...

You may also be interested in...

Judge rules for Red Cross over Johnson & Johnson

The American Red Cross can lawfully use its Red Cross emblem on commercial products, despite J&J's contention that it violates its rights to the design, New York federal judge Jed Rakoff rules May 14. J&J filed the suit in August 2007 (1"The Gray Sheet" Aug. 13, 2007, In Brief). Rakoff ruled against American Red Cross counterclaims that Johnson & Johnson was violating the trademark rights

COVID-19 Pandemic Accelerates Shift Toward Virtual Trials

As the global shut-down caused by the coronavirus pandemic continues, sponsors are rushing to adapt clinical trials that can move to partial or completely remote monitoring, allowing patients to remain in their homes but continue to participate in studies. And the outbreak may have another silver lining for the biopharma industry, a chance to rebuild its reputation. 

mRNA Vaccines – Trials Line Up Against Coronavirus

The arrival of SARS-CoV-2 has focused attention on a potential new way of making vaccines – one that promises to be quicker and cheaper than traditional methods and more reactive to novel virus outbreaks, but also one that remains to be validated.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts